NCT06291116View on ClinicalTrials.gov

Safety of RotigotiNe in Patients With Autosomal Dominant Polycystic Kidney Disease

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

May 1, 2029

Study Completion Date

May 1, 2029

Conditions
Kidney Diseases
Interventions
DRUG

standard care + rotigotine at 4 mg/24h for 24 months.

standard care + rotigotine at 4 mg/24h for 24 months.

DRUG

standard care for 24 months.

standard care for 24 months.

All Listed Sponsors
lead

University Hospital, Rouen

OTHER